PCLOF (PharmaCielo) 10-Year ROIIC % : -589.29% (As of Dec. 2023)


What is PharmaCielo 10-Year ROIIC %?

PharmaCielo PCLOF -13.21% 10-Year ROIIC % is -589.29 as of Dec. 2023. The stock has 5 warning signs investors should review. Among 857 Drug Manufacturers companies, PharmaCielo ranks worse than 98.72% on this metric.

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. PharmaCielo does not have enough data to calculate 10-Year ROIIC %.


PharmaCielo  (OTCPK:PCLOF) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


PharmaCielo 10-Year ROIIC % Related Terms


PharmaCielo 10-Year ROIIC % Historical Data

* Premium members only.

The historical data trend for PharmaCielo's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCielo 10-Year ROIIC % Chart

PharmaCielo Annual Data
Trend Aug17 Aug18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year ROIIC %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

PharmaCielo Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25 Dec25
10-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PCLOF vs ZTS, UTHR: 10-Year ROIIC % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, PharmaCielo's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaCielo 10-Year ROIIC % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PharmaCielo's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where PharmaCielo's 10-Year ROIIC % falls into.



PharmaCielo 10-Year ROIIC % Calculation

PharmaCielo's 10-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

10-Year ROIIC %=10-Year Incremental Net Operating Profit After Taxes (NOPAT)**/10-Year Incremental Invested Capital**
=( -7.486 (Dec. 2023) - (Dec. 2013) )/( 25.898 (Dec. 2023) - (Dec. 2013) )
=/
=N/A%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Frequently Asked Questions Learn more about 10-Year ROIIC % →
What does a 10-Year ROIIC % of -589.29 mean?
PharmaCielo (PCLOF) has a 10-Year ROIIC % of -589.29 as of Dec. 2023. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on PharmaCielo and its competitors. According to the industry distribution chart, PharmaCielo ranks #846 out of 857 companies in the Drug Manufacturers industry, placing it in the top 98.7%.
Is PharmaCielo's 10-Year ROIIC % too high?
PharmaCielo's current 10-Year ROIIC % is -589.29. Based on the distribution chart, PharmaCielo ranks #846 out of 857 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does PharmaCielo's 10-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PharmaCielo ranks #846 out of 857 companies for 10-Year ROIIC %. This places PharmaCielo in the lower half of its industry. The industry median 10-Year ROIIC % is 4.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Drug Manufacturers company?
The median 10-Year ROIIC % among Drug Manufacturers companies is 4.44, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on PharmaCielo and its competitors. For the Drug Manufacturers industry, the median 10-Year ROIIC % is 4.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCielo's current 10-Year ROIIC % is -589.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.11, compared to a current price of $0.05 — trading 51.6% below its estimated fair value. The current 10-Year ROIIC % is -589.29. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current 10-Year ROIIC % is -589.29 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCielo Business Description

Other Exchanges PCLO:Canada
Address 82 Richmond Street East, Suite 805, Toronto, ON, CAN, M5C 1P1
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.